StratifAI has raised EUR 12.5 million to fast-track the clinical validation of its AI-powered biomarker platform, Polaris™, aimed at transforming cancer diagnostics in the precision oncology market.

Target Information

StratifAI, a Berlin-based precision oncology company, has successfully raised EUR 12.5 million in a funding round aimed at validating its innovative AI biomarker platform, Polaris™. This platform is designed for the rapid and cost-effective discovery of cancer biomarkers, addressing an urgent need in the oncology field for enhanced precision in diagnostics. The funding round was led by Picus Capital in collaboration with Alven, alongside support from notable investors such as Heliad, Rubin Ritter, Lars Langusch, and Jens Begemann. Existing investors including Debiopharm and Arve Capital also participated, demonstrating strong confidence in StratifAI's strategic direction.

Polaris™ has the potential to revolutionize biomarker discovery by utilizing a fully digital, AI-driven approach that simplifies the traditional, labor-intensive processes. StratifAI's technology integrates routine histology with RNA sequencing data, enabling significant advancements in the identification of prognostic and predictive biomarkers for various solid tumors. The company is currently focusing on its first clinical application, Polaris™ Breast, which evaluates the risk of breast cancer recurrence through automated analysis of histological slides.

Industry Overview

The landscape of cancer diagnostics in Europe is rapidly evolving, with significant advancements being made in precision medicine. Despite these advancements, there remains a considerable gap in effective biomarker discovery which hamper